低分子肝素药理学机制及适应证研究进展

Research progress on pharmacological mechanism of LMWH and its clinical indications

低分子肝素是由普通肝素经降解得到的分子量较小的肝素片断,与未分级肝素相比,具有较低的分子量、更好的抗Xa活性、低使用剂量时具有更好的效果、半衰期长、临床效应可预测性强。本文简要介绍了低分子肝素的药理学机制及适应证研究进展。

Low-molecular-weight heparin（ LMWH） is obtained by various methods of fractionation or depolymerisation of polymeric heparin. Compare to unfractionated heparin（ UFH）,LMWH have relatively smaller molecular weight,better anti-Xa activity,greater bioavailability at low doses,longer half-life and more predictable anticoagulant response when administered in fixed doses. This article described the pharmacological mechanism of LMWH and their clinical indications.